7,10,13,16-Eicosatetraenoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 7,10,13,16-Eicosatetraenoic acid
• 英文别名: icosa-7,10,13,16-tetraenoic acid
• 化学式: C₂₀H₃₂O₂
• 分子量: 304.5
• InChiKey: QCPSKUPOPPPLSP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  22
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• PHARMACEUTICAL COMPOSITION FOR LOWERING BLOOD SUGAR LEVEL
  申请人：PHARMAFRONTIER CO., LTD.

  公开号：EP1731602A1

  公开（公告）日：2006-12-13

  An object of the invention is to provide a pharmaceutical composition and a kit therefor for the lowering of elevated blood sugar level associated with diabetes and for the prevention of the elevation of blood sugar level. The invention provides a pharmaceutical composition containing a ligand (agonist or antagonist) for a GT01 polypeptide, particularly a free fatty acid as a GT01 polypeptide-specific ligand, or a GT01 gene or the GT01 polypeptide, for treating the hyperglycemia associated with diabetes, and a kit therefor. The invention also provides a ligand specific for the GT01 polypeptide, and a screening method exerting an influence on the binding of the specific ligand to the GT01 polypeptide.

  本发明的目的是提供一种药物组合物及其试剂盒，用于降低与糖尿病相关的血糖水平升高和预防血糖水平升高。本发明提供了一种药物组合物，其中含有 GT01 多肽的配体（激动剂或拮抗剂），特别是作为 GT01 多肽特异性配体的游离脂肪酸，或 GT01 基因或 GT01 多肽，用于治疗与糖尿病相关的高血糖症，以及相关的试剂盒。本发明还提供了一种 GT01 多肽特异配体，以及一种影响特异配体与 GT01 多肽结合的筛选方法。
• Pharmaceutical Composition for Lowering Blood Sugar Level
  申请人：Hirasawa Akira

  公开号：US20080004227A1

  公开（公告）日：2008-01-03

  An object of the invention is to provide a pharmaceutical composition and a kit therefor for the lowering of elevated blood sugar level associated with diabetes and for the prevention of the elevation of blood sugar level. The invention provides a pharmaceutical composition containing a ligand (agonist or antagonist) for a GT01 polypeptide, particularly a free fatty acid as a GT01 polypeptide-specific ligand, or a GT01 gene or the GT01 polypeptide, for treating the hyperglycemia associated with diabetes, and a kit therefor. The invention also provides a ligand specific for the GT01 polypeptide, and a screening method exerting an influence on the binding of the specific ligand to the GT01 polypeptide.